All Stories

  1. Inflammation in Atrial Fibrillation–Related Stroke

    Article • Neurology, March 2026, Wolters Kluwer Health

    MD Pietro Enea Lazzerini

  2. Anti-Ro/SSA-antibody testing for isolated atrioventricular block in adults: a diagnostic and therapeutic work-up

    Article • European Heart Journal, March 2026, Oxford University Press (OUP)

    MD Pietro Enea Lazzerini

  3. hERG epitope mimic-decoy peptide corrects autoimmune-long QT syndrome in guinea pigs

    Article • Communications Medicine, March 2026, Springer Science + Business Media

    MD Pietro Enea Lazzerini

  4. Kinase-driven inflammasome resolution: shifting the paradigm for atherosclerosis management

    Article • European Heart Journal, February 2026, Oxford University Press (OUP)

    MD Pietro Enea Lazzerini

  5. REPLY

    Article • JACC Clinical Electrophysiology, February 2026, Elsevier

    MD Pietro Enea Lazzerini

  6. Sex Hormone Profiles in Patients With Torsades de Pointes Ventricular Tachycardia

    Article • JACC Clinical Electrophysiology, November 2025, Elsevier

    MD Pietro Enea Lazzerini

  7. Androgen Replacement Therapy for Torsades de Pointes in Males: Hormonal Modulation as a Novel Antiarrhythmic Strategy

    Article • Journal of Cardiovascular Pharmacology, October 2025, Wolters Kluwer Health

    MD Pietro Enea Lazzerini

  8. Urinary tract infections caused by Gram-negative bacteria in elderly hospitalized patients: Epidemiology, clinical features and outcomes in the era of antimicrobial resistance

    Article • Journal of Global Antimicrobial Resistance, September 2025, Elsevier

    MD Pietro Enea Lazzerini

  9. Hepatitis C Virus Opportunistic Screening in South-Eastern Tuscany Residents Admitted to the University Hospital in Siena

    Article • Livers, June 2025, MDPI AG

    MD Pietro Enea Lazzerini

  10. Autoimmune cardiac channelopathies and heart rhythm disorders: A contemporary review

    Article • Heart Rhythm, June 2025, Elsevier

    MD Pietro Enea Lazzerini

  11. Postural Orthostatic Tachycardia Syndrome and Orthostatic Hypotension Following Hematopoietic Stem Cell Transplantation

    Article • JACC CardioOncology, June 2025, Elsevier

    MD Pietro Enea Lazzerini

  12. Searching for biomarkers of atrial cardiomyopathy at high risk of cardioembolism: What are the missing pieces of the puzzle?

    Article • European Stroke Journal, June 2025, Oxford University Press (OUP)

    MD Pietro Enea Lazzerini

  13. Impact of Hospitalization on Sarcopenia, NADPH-Oxidase 2, Oxidative Stress, and Low-Grade Endotoxemia in Elderly Patients

    Article • Antioxidants, March 2025, MDPI AG

    MD Pietro Enea Lazzerini

  14. Atrial Thrombogenicity and Residual Stroke Risk in Atrial Fibrillation

    Article • Neurology, January 2025, Wolters Kluwer Health

    MD Pietro Enea Lazzerini

  15. Pro-arrhythmic potential of proton-pump inhibitors

    Article • Nature Reviews Cardiology, December 2024, Springer Science + Business Media

    MD Pietro Enea Lazzerini

  16. Rate and predictors of thromboprophylaxis in internal medicine wards: Results from the AURELIO study

    Article • Thrombosis Research, November 2024, Elsevier

    MD Pietro Enea Lazzerini

  17. Ventricular arrhythmias after atrial fibrillation electrical cardioversion: A multicenter study

    Article • Heart Rhythm O2, November 2024, Elsevier

    MD Pietro Enea Lazzerini

  18. Editorial: Case reports in general cardiovascular medicine: 2023

    Article • Frontiers in Cardiovascular Medicine, August 2024, Frontiers

    MD Pietro Enea Lazzerini

  19. Hydroxychloroquine, Chloroquine, and Arrhythmic Risk in Systemic Autoimmune Diseases: Focus More on the Patient and You Will Keep the Rhythm!

    Article • Journal of Cardiovascular Pharmacology, August 2024, Wolters Kluwer Health

    MD Pietro Enea Lazzerini

  20. Life-Threatening Arrhythmias in Patients With Takotsubo Syndrome

    Article • JACC Clinical Electrophysiology, August 2024, Elsevier

    MD Pietro Enea Lazzerini

  21. Increased interleukin‐6 levels are associated with atrioventricular conduction delay in severe COVID‐19 patients

    Article • Journal of Arrhythmia, July 2024, Wiley

    MD Pietro Enea Lazzerini

  22. The Impact of Sex and Arterial Stiffness Interactions on the Outcome after an Acute Ischemic Stroke: A Retrospective Cohort Study

    Article • Journal of Clinical Medicine, July 2024, MDPI AG

    MD Pietro Enea Lazzerini

  23. Advanced Atrioventricular Block in Athletes: Prevalence and Role of Anti‐Ro/Sjögren Syndrome–Related Antigen A Antibodies

    Article • Journal of the American Heart Association, June 2024, Wolters Kluwer Health

    MD Pietro Enea Lazzerini

  24. Myocarditis and Arrhythmias

    Article • JACC Clinical Electrophysiology, June 2024, Elsevier

    MD Pietro Enea Lazzerini

  25. Elevated Interleukin‐6 Levels Are Associated With an Increased Risk of QTc Interval Prolongation in a Large Cohort of US Veterans

    Article • Journal of the American Heart Association, February 2024, Wolters Kluwer Health

    MD Pietro Enea Lazzerini

  26. Editorial: Year in review: discussions in general cardiovascular medicine

    Article • Frontiers in Cardiovascular Medicine, December 2023, Frontiers

    MD Pietro Enea Lazzerini

  27. Pathogenic pathways and therapeutic targets of inflammation in heart diseases: A focus on Interleukin‐1

    Article • European Journal of Clinical Investigation, October 2023, Wiley

    MD Pietro Enea Lazzerini

  28. Editorial: Case reports in general cardiovascular medicine: 2022

    Article • Frontiers in Cardiovascular Medicine, August 2023, Frontiers

    MD Pietro Enea Lazzerini

  29. Editorial: New challenges and future perspectives in autonomic neuroscience

    Article • Frontiers in Neuroscience, August 2023, Frontiers

    MD Pietro Enea Lazzerini

  30. Editorial: Insights in general cardiovascular medicine: 2022

    Article • Frontiers in Cardiovascular Medicine, August 2023, Frontiers

    MD Pietro Enea Lazzerini

  31. Anti-Ro/SSA Antibodies Blocking Calcium Channels as a Potentially Reversible Cause of Atrioventricular Block in Adults

    Article • JACC Clinical Electrophysiology, August 2023, Elsevier

    MD Pietro Enea Lazzerini

  32. Fir(e)ing the Rhythm

    Article • JACC Basic to Translational Science, June 2023, Elsevier

    MD Pietro Enea Lazzerini

  33. Reply

    Article • JACC Basic to Translational Science, June 2023, Elsevier

    MD Pietro Enea Lazzerini

  34. Contribution of cytokine-mediated prolongation of QTc interval to the multi-hit theory of Torsade de Pointes

    Article • Biochemical and Biophysical Research Communications, May 2023, Elsevier

    MD Pietro Enea Lazzerini

  35. Cryptogenic stroke as a working diagnosis: the need for an early and comprehensive diagnostic work-up

    Article • BMC Neurology, April 2023, Springer Science + Business Media

    MD Pietro Enea Lazzerini

  36. Worldwide survey on implantation of and outcomes for conduction system pacing with His bundle and left bundle branch area pacing leads

    Article • Journal of Interventional Cardiac Electrophysiology, January 2023, Springer Science + Business Media

    MD Pietro Enea Lazzerini

  37. Targeting IL-6 in COVID-19. Response to: ‘Rational use of tocilizumab in COVID-19‘ by Jain and Sharma

    Article • Annals of the Rheumatic Diseases, November 2022, Elsevier

    MD Pietro Enea Lazzerini

  38. Anti-Ro/SSA-antibodies and heart rhythm disturbances in the general population: the ‘dark side of the immune’

    Article • European Heart Journal, October 2022, Oxford University Press (OUP)

    MD Pietro Enea Lazzerini

  39. Maternal Anti-Ro/SSA Autoantibodies and Prolonged PR Interval in a Competitive Athlete

    Article • JACC Case Reports, September 2022, Elsevier

    MD Pietro Enea Lazzerini

  40. Safety of Intravenous Thrombolysis and Mechanical Thrombectomy in Bilateral Posterior Cerebral Artery Territory Infarction

    Article • Current Drug Safety, August 2022, Bentham Science Publishers

    MD Pietro Enea Lazzerini

  41. Editorial: Insights in General Cardiovascular Medicine: 2021

    Article • Frontiers in Cardiovascular Medicine, July 2022, Frontiers

    MD Pietro Enea Lazzerini

  42. Anti-Ca v 1.2 Antibody–Induced Atrioventricular Block as a Novel Form in the Adult: Long-Term Pacemaker-Sparing Activity of Hydroxychloroquine

    Article • Circulation Arrhythmia and Electrophysiology, July 2022, Wolters Kluwer Health

    MD Pietro Enea Lazzerini

  43. Markers of Atrial Cardiopathy in Severe Embolic Strokes of Undetermined Source

    Article • Frontiers in Cardiovascular Medicine, June 2022, Frontiers

    MD Pietro Enea Lazzerini

  44. Editorial: Highlights in General Cardiovascular Medicine: 2021

    Article • Frontiers in Cardiovascular Medicine, May 2022, Frontiers

    MD Pietro Enea Lazzerini

  45. Interleukin-6 Elevation Is a Key Pathogenic Factor Underlying COVID-19-Associated Heart Rate-Corrected QT Interval Prolongation

    Article • Frontiers in Cardiovascular Medicine, May 2022, Frontiers

    MD Pietro Enea Lazzerini

  46. P-wave dispersion as a marker of atrial cardiopathy in embolic stroke of undetermined source

    Article • European Journal of Internal Medicine, May 2022, Elsevier

    MD Pietro Enea Lazzerini

  47. Inflammatory cytokines and cardiac arrhythmias: the lesson from COVID-19

    Article • Nature Reviews Immunology, March 2022, Springer Science + Business Media

    MD Pietro Enea Lazzerini

  48. Implantation of cardiac electronic devices in active COVID-19 patients: Results from an international survey

    Article • Heart Rhythm, February 2022, Elsevier

    MD Pietro Enea Lazzerini

  49. Arrhythmogenic mechanisms of interleukin-6 combination with hydroxychloroquine and azithromycin in inflammatory diseases

    Article • Scientific Reports, January 2022, Springer Science + Business Media

    MD Pietro Enea Lazzerini

  50. Off‐Label Use of Hydroxychloroquine in COVID‐19: Analysis of Reports of Suspected Adverse Reactions From the Italian National Network of Pharmacovigilance

    Article • The Journal of Clinical Pharmacology, January 2022, Wiley

    MD Pietro Enea Lazzerini

  51. Transient Hypogonadism Is Associated With Heart Rate–Corrected QT Prolongation and Torsades de Pointes Risk During Active Systemic Inflammation in Men

    Article • Journal of the American Heart Association, January 2022, Wolters Kluwer Health

    MD Pietro Enea Lazzerini

  52. Unravelling Atrioventricular Block Risk in Inflammatory Diseases: Systemic Inflammation Acutely Delays Atrioventricular Conduction via a Cytokine‐Mediated Inhibition of Connexin43 Expression

    Article • Journal of the American Heart Association, November 2021, Wolters Kluwer Health

    MD Pietro Enea Lazzerini

  53. Comment on “Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty?”

    Article • Journal of Hepatology, October 2021, Elsevier

    MD Pietro Enea Lazzerini

  54. Anti-Ro/SSA Antibodies and the Autoimmune Long-QT Syndrome

    Article • Frontiers in Medicine, September 2021, Frontiers

    MD Pietro Enea Lazzerini

  55. Outcome After Acute Ischemic Stroke Treatment During Covid-19 Outbreak in South-East Tuscany

    Article • Cardiovascular & Haematological Disorders - Drug Targets, September 2021, Bentham Science Publishers

    MD Pietro Enea Lazzerini

  56. Proton Pump Inhibitors Directly Block hERG-Potassium Channel and Independently Increase the Risk of QTc Prolongation in a Large Cohort of US Veterans

    Article • Circulation Arrhythmia and Electrophysiology, July 2021, Wolters Kluwer Health

    MD Pietro Enea Lazzerini

  57. Roxithromycin-Associated Acute Thrombocytopenia

    Article • American Journal of Case Reports, May 2021, International Scientific Literature

    MD Pietro Enea Lazzerini

  58. Drug-Associated QTc Prolongation in Geriatric Hospitalized Patients: A Cross-Sectional Study in Internal Medicine

    Article • Drugs - Real World Outcomes, April 2021, Springer Science + Business Media

    MD Pietro Enea Lazzerini

  59. Increased Arterial Stiffness is a Predictor of Delayed Ischaemic Stroke After Subarachnoid Haemorrhage

    Article • Heart Lung and Circulation, April 2021, Elsevier

    MD Pietro Enea Lazzerini

  60. Risk of QTc Interval Prolongation Associated With Circulating Anti‐Ro/SSA Antibodies Among US Veterans: An Observational Cohort Study

    Article • Journal of the American Heart Association, February 2021, Wolters Kluwer Health

    MD Pietro Enea Lazzerini

  61. Worldwide Survey of COVID-19 Associated Arrhythmias

    Article • Circulation Arrhythmia and Electrophysiology, February 2021, Wolters Kluwer Health

    Keith Sai Kit Leung, Prof Anna Vittoria Mattioli, MD Pietro Enea Lazzerini

  62. Letter by Acampa et al Regarding Article, “Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage in Patients With a History of Migraine”

    Article • Stroke, February 2021, Wolters Kluwer Health

    MD Pietro Enea Lazzerini

  63. Neutrophil extracellular traps release in gout and pseudogout depends on the number of crystals regardless of leukocyte count

    Article • Rheumatology, January 2021, Oxford University Press (OUP)

    MD Pietro Enea Lazzerini

  64. Antirheumatic agents in covid-19: is IL-6 the right target?

    Article • Annals of the Rheumatic Diseases, January 2021, Elsevier

    MD Pietro Enea Lazzerini

  65. Letter by Lazzerini et al Regarding Article, “Autoantibody Signature in Cardiac Arrest”

    Article • Circulation, November 2020, Wolters Kluwer Health

    MD Pietro Enea Lazzerini

  66. IL-6 (Interleukin 6) Blockade and Heart Rate Corrected QT Interval Prolongation in COVID-19

    Article • Circulation Arrhythmia and Electrophysiology, September 2020, Wolters Kluwer Health

    MD Pietro Enea Lazzerini

  67. Cardiac Arrest Risk During Acute Infections

    Article • Circulation Arrhythmia and Electrophysiology, August 2020, Wolters Kluwer Health

    MD Pietro Enea Lazzerini

  68. Non-stenosing Carotid Atherosclerosis and Arterial Stiffness in Embolic Stroke of Undetermined Source

    Article • Frontiers in Neurology, July 2020, Frontiers

    MD Pietro Enea Lazzerini

  69. COVID-19, Arrhythmic Risk, and Inflammation

    Article • Circulation, July 2020, Wolters Kluwer Health

    MD Pietro Enea Lazzerini

  70. Androgen Deprivation Therapy for Prostatic Cancer in Patients With Torsades de Pointes

    Article • Frontiers in Pharmacology, May 2020, Frontiers

    MD Pietro Enea Lazzerini

  71. A Novel Peptide/Antibody-Based Antiarrhythmic Approach to Long QT Syndrome and Beyond

    Article • Journal of the American College of Cardiology, May 2020, Elsevier

    MD Pietro Enea Lazzerini

  72. Commentary: Systemic effects of IL-17 in inflammatory arthritis

    Article • Frontiers in Cardiovascular Medicine, December 2019, Frontiers

    MD Pietro Enea Lazzerini

  73. Editorial: Cardioimmunology: Inflammation and Immunity in Cardiovascular Disease

    Article • Frontiers in Cardiovascular Medicine, December 2019, Frontiers

    MD Pietro Enea Lazzerini

  74. Electrocardiographic Predictors of Silent Atrial Fibrillation in Cryptogenic Stroke

    Article • Heart Lung and Circulation, November 2019, Elsevier

    MD Pietro Enea Lazzerini

  75. P Wave Dispersion and Silent Atrial Fibrillation in Cryptogenic Stroke: The Pathogenic Role of Inflammation

    Article • Cardiovascular & Haematological Disorders - Drug Targets, October 2019, Bentham Science Publishers

    MD Pietro Enea Lazzerini

  76. Inflammatory cytokines, life-threatening arrhythmias and premature mortality in chronic inflammatory arthritis: time to focus on

    Article • Annals of the Rheumatic Diseases, September 2019, Elsevier

    MD Pietro Enea Lazzerini

  77. Systemic Inflammation Rapidly Induces Reversible Atrial Electrical Remodeling: The Role of Interleukin‐6–Mediated Changes in Connexin Expression

    Article • Journal of the American Heart Association, August 2019, Wolters Kluwer Health

    MD Pietro Enea Lazzerini

  78. Autoimmune and inflammatory K+ channelopathies in cardiac arrhythmias: Clinical evidence and molecular mechanisms

    Article • Heart Rhythm, August 2019, Elsevier

    MD Pietro Enea Lazzerini

  79. Inflammation and Atrial Electrical Remodelling in Patients With Embolic Strokes of Undetermined Source

    Article • Heart Lung and Circulation, June 2019, Elsevier

    MD Pietro Enea Lazzerini

  80. Autoimmune Calcium Channelopathies and Cardiac Electrical Abnormalities

    Article • Frontiers in Cardiovascular Medicine, May 2019, Frontiers

    Martin Ibarrola, MD Pietro Enea Lazzerini

  81. Cardioimmunology of arrhythmias: the role of autoimmune and inflammatory cardiac channelopathies

    Article • Nature Reviews Immunology, December 2018, Springer Science + Business Media

    MD Pietro Enea Lazzerini

  82. Interleukin-6 inhibition of hERG underlies risk for acquired long QT in cardiac and systemic inflammation

    Article • PLOS One, December 2018, PLOS

    MD Pietro Enea Lazzerini

  83. Emerging Arrhythmic Risk of Autoimmune and Inflammatory Cardiac Channelopathies

    Article • Journal of the American Heart Association, November 2018, Wolters Kluwer Health

    MD Pietro Enea Lazzerini

  84. Perioperative stroke and hyperhomocysteinemia: a possible pathogenic link

    Article • Korean Journal of Anesthesiology, August 2018, The Korean Society of Anesthesiologists (KAMJE)

    MD Pietro Enea Lazzerini

  85. Atrial Cardiopathy and Sympatho-Vagal Imbalance in Cryptogenic Stroke: Pathogenic Mechanisms and Effects on Electrocardiographic Markers

    Article • Frontiers in Neurology, June 2018, Frontiers

    MD Pietro Enea Lazzerini

  86. Increased Arterial Stiffness is Associated with Poor Collaterals in Acute Ischemic Stroke from Large Vessel Occlusion

    Article • Current Neurovascular Research, May 2018, Bentham Science Publishers

    MD Pietro Enea Lazzerini

  87. Proton Pump Inhibitors and Serum Magnesium Levels in Patients With Torsades de Pointes

    Article • Frontiers in Pharmacology, April 2018, Frontiers

    MD Pietro Enea Lazzerini

  88. Torsades de Pointes in Patients with Polymyalgia Rheumatica

    Article • Current Pharmaceutical Design, April 2018, Bentham Science Publishers

    MD Pietro Enea Lazzerini

  89. Previous use of Statins and Atrial Electrical Remodeling in Patients with Cryptogenic Stroke

    Article • Cardiovascular & Haematological Disorders - Drug Targets, February 2018, Bentham Science Publishers

    MD Pietro Enea Lazzerini, Dr Maurizio Acampa, Rossana Tassi

  90. Non-HCV-related cryoglobulinemic vasculitis and parvovirus-B19 infection

    Article • Joint Bone Spine, January 2018, Elsevier

    MD Pietro Enea Lazzerini

  91. Postoperative atrial fibrillation and ischemic stroke: The role of homocysteine

    Article • European Stroke Journal, September 2017, SAGE Publications

    Dr Maurizio Acampa, MD Pietro Enea Lazzerini

  92. Searching Novel Therapeutic Targets for Scleroderma: P2X7-Receptor Is Up-regulated and Promotes a Fibrogenic Phenotype in Systemic Sclerosis Fibroblasts

    Article • Frontiers in Pharmacology, September 2017, Frontiers

    MD Pietro Enea Lazzerini

  93. Increased arterial stiffness is an independent risk factor for hemorrhagic transformation in ischemic stroke undergoing thrombolysis

    Article • International Journal of Cardiology, September 2017, Elsevier

    MD Pietro Enea Lazzerini

  94. Autoimmune cardiac channelopathies: the heart of the matter

    Article • Nature Reviews Cardiology, July 2017, Springer Science + Business Media

    MD Pietro Enea Lazzerini

  95. How to Identify Patients at Risk of Silent Atrial Fibrillation after Cryptogenic Stroke: Potential Role of P Wave Dispersion

    Article • Journal of Stroke, May 2017, Korean Stroke Society (KAMJE)

    Dr Maurizio Acampa, MD Pietro Enea Lazzerini

  96. Systemic inflammation as a novel QT-prolonging risk factor in patients with torsades de pointes

    Article • Heart, May 2017, BMJ

    MD Pietro Enea Lazzerini

  97. Autoimmune channelopathies as a novel mechanism in cardiac arrhythmias

    Article • Nature Reviews Cardiology, May 2017, Springer Science + Business Media

    MD Pietro Enea Lazzerini

  98. Combination Therapy With Ceftriaxone and Lansoprazole, Acquired Long QT Syndrome, and Torsades de Pointes Risk

    Article • Journal of the American College of Cardiology, April 2017, Elsevier

    MD Pietro Enea Lazzerini

  99. Assessing QT interval in patients with autoimmune chronic inflammatory diseases: perils and pitfalls

    Article • Lupus Science & Medicine, December 2016, BMJ

    MD Pietro Enea Lazzerini

  100. Adenosine receptors expression in cardiac fibroblasts of patients with left ventricular dysfunction due to valvular disease

    Article • Journal of Receptors and Signal Transduction, November 2016, Taylor & Francis

    MD Pietro Enea Lazzerini

  101. Letter by Acampa et al Regarding Article, “Underutilization of Ambulatory ECG Monitoring After Stroke and Transient Ischemic Attack: Missed Opportunities for Atrial Fibrillation Detection”

    Article • Stroke, October 2016, Wolters Kluwer Health

    Dr Maurizio Acampa, MD Pietro Enea Lazzerini

  102. Marked QTc Prolongation and Torsades de pointes in Patients with Chronic Inflammatory Arthritis

    Article • Frontiers in Cardiovascular Medicine, September 2016, Frontiers

    Dr Maurizio Acampa, MD Pietro Enea Lazzerini

  103. Spotlight on sirukumab for the treatment of rheumatoid arthritis: the evidence to date

    Article • Drug Design Development and Therapy, September 2016, Dove Medical Press

    MD Pietro Enea Lazzerini, Dr Maurizio Acampa

  104. To the Editor— Carnitine and ventricular repolarization: a complex link?

    Article • Heart Rhythm, August 2016, Elsevier

    Dr Maurizio Acampa, MD Pietro Enea Lazzerini

  105. Induction of autoimmune response to the extracellular loop of the HERG channel pore induces QTc prolongation in guinea‐pigs

    Article • The Journal of Physiology, July 2016, Wiley

    MD Pietro Enea Lazzerini

  106. Biologic drugs and arrhythmic risk in chronic inflammatory arthritis: the good and the bad

    Article • Immunologic Research, July 2016, Springer Science + Business Media

    MD Pietro Enea Lazzerini

  107. Inflammation and arrhythmic risk in rheumatoid arthritis

    Article • European Heart Journal, June 2016, European Society of Cardiology

    MD Pietro Enea Lazzerini

  108. Potassium Channel Block and Novel Autoimmune-Associated Long QT Syndrome

    Article • Cardiac Electrophysiology Clinics, June 2016, Elsevier

    MD Pietro Enea Lazzerini

  109. Ischemic Stroke after Heart Transplantation

    Article • Journal of Stroke, May 2016, Korean Stroke Society (KAMJE)

    Dr Maurizio Acampa, MD Pietro Enea Lazzerini

  110. Arrhythmogenicity of Anti-Ro/SSA Antibodies in Patients With Torsades de Pointes

    Article • Circulation Arrhythmia and Electrophysiology, March 2016, Wolters Kluwer Health

    Dr Maurizio Acampa, MD Pietro Enea Lazzerini

  111. Isolated atrioventricular block of unknown origin in the adult and autoimmunity: diagnostic and therapeutic considerations exemplified by 3 anti-Ro/SSA–associated cases

    Article • HeartRhythm Case Reports, September 2015, Elsevier

    MD Pietro Enea Lazzerini

  112. The role of P2X7 receptors in tissue fibrosis: a brief review

    Article • Purinergic Signalling, August 2015, Springer Science + Business Media

    MD Pietro Enea Lazzerini

  113. Pathogenesis of the Novel Autoimmune-Associated Long-QT Syndrome

    Article • Circulation, July 2015, Wolters Kluwer Health

    MD Pietro Enea Lazzerini

  114. P wave dispersion in cryptogenic stroke: A risk factor for cardioembolism?

    Article • International Journal of Cardiology, July 2015, Elsevier

    Dr Maurizio Acampa, MD Pietro Enea Lazzerini

  115. Long QT Syndrome: An Emerging Role for Inflammation and Immunity

    Article • Frontiers in Cardiovascular Medicine, May 2015, Frontiers

    MD Pietro Enea Lazzerini

  116. Comment on “Absence of an association between anti-Ro antibodies and prolonged QTc interval in systemic sclerosis: A multicenter study of 689 patients”

    Article • Seminars in Arthritis and Rheumatism, April 2015, Elsevier

    MD Pietro Enea Lazzerini

  117. Antiarrhythmic Potential of Anticytokine Therapy in Rheumatoid Arthritis: Tocilizumab Reduces Corrected QT Interval by Controlling Systemic Inflammation

    Article • Arthritis Care & Research, February 2015, Wiley

    MD Pietro Enea Lazzerini, Dr Maurizio Acampa

  118. Clinically-relevant cyclosporin and rapamycin concentrations enhance regulatory T cell function to a similar extent but with different mechanisms: An in-vitro study in healthy humans

    Article • International Immunopharmacology, February 2015, Elsevier

    MD Pietro Enea Lazzerini

  119. Isolated atrioventricular block of unknown origin in adults and anti-Ro/SSA antibodies: Clinical evidence, putative mechanisms, and therapeutic implications

    Article • Heart Rhythm, February 2015, Elsevier

    MD Pietro Enea Lazzerini

  120. Cerebellar haemorrhage, factor XI deficiency and concomitant risk factors: Figure 1.

    Article • QJM, January 2015, Oxford University Press (OUP)

    MD Pietro Enea Lazzerini

  121. Arrhythmic risk in rheumatoid arthritis: the driving role of systemic inflammation

    Article • Autoimmunity Reviews, September 2014, Elsevier

    Dr Maurizio Acampa, MD Pietro Enea Lazzerini

  122. The purinergic P2×7 receptor is expressed on monocytes in Behçet's disease and is modulated by TNF‐α

    Article • European Journal of Immunology, October 2013, Wiley

    Luca Cantarini, MD Pietro Enea Lazzerini

  123. Statins as a New Therapeutic Perspective in Myocarditis and Postmyocarditis Dilated Cardiomyopathy

    Article • Cardiovascular Drugs and Therapy, July 2013, Springer Science + Business Media

    MD Pietro Enea Lazzerini

  124. Association between high sensitivity C-reactive protein, heart rate variability and corrected QT interval in patients with chronic inflammatory arthritis

    Article • European Journal of Internal Medicine, June 2013, Elsevier

    Dr Maurizio Acampa, MD Pietro Enea Lazzerini

  125. Rosuvastatin inhibits spontaneous and IL-1β-induced interleukin-6 production from human cultured osteoblastic cells

    Article • Joint Bone Spine, March 2013, Elsevier

    MD Pietro Enea Lazzerini

  126. Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis

    Article • Annals of the Rheumatic Diseases, September 2012, Elsevier

    MD Pietro Enea Lazzerini

  127. Adenosine A2A receptor activation stimulates collagen production in sclerodermic dermal fibroblasts either directly and through a cross-talk with the cannabinoid system

    Article • Journal of Molecular Medicine, October 2011, Springer Science + Business Media

    MD Pietro Enea Lazzerini

  128. Comment on: Letter to the Editor from Clockaerts and Bierma-Zeinstra

    Article • Seminars in Arthritis and Rheumatism, October 2011, Elsevier

    MD Pietro Enea Lazzerini

  129. Anti-Ro/SSA-associated corrected QT interval prolongation in adults: The role of antibody level and specificity

    Article • Arthritis Care & Research, September 2011, Wiley

    Dr Maurizio Acampa, MD Pietro Enea Lazzerini

  130. The “Invulnerability” of the Adult Conduction System to Anti‐Ro/SSA Antibodies? A Matter of Calcium Channel Expression on the Cardiomyocyte

    Article • Journal of Cardiovascular Electrophysiology, June 2011, Wiley

    MD Pietro Enea Lazzerini

  131. Statins and the Joint: Multiple Targets for a Global Protection?

    Article • Seminars in Arthritis and Rheumatism, April 2011, Elsevier

    MD Pietro Enea Lazzerini

  132. Homocysteine and P wave dispersion in patients with heart transplantation

    Article • Clinical Transplantation, January 2011, Wiley

    Dr Maurizio Acampa, MD Pietro Enea Lazzerini

  133. Levels of circulating CXCR4-positive cells are decreased and negatively correlated with risk factors in cardiac transplant recipients

    Article • Heart and Vessels, October 2010, Springer Science + Business Media

    MD Pietro Enea Lazzerini

  134. Anti-Ro/SSA Antibodies and Cardiac Arrhythmias in the Adult: Facts and Hypotheses

    Article • Scandinavian Journal of Immunology, June 2010, Wiley

    MD Pietro Enea Lazzerini

  135. Homocysteine and Raynaud's phenomenon: A review

    Article • Autoimmunity Reviews, January 2010, Elsevier

    MD Pietro Enea Lazzerini

  136. Arrhythmogenic effects of anti-Ro/SSA antibodies on the adult heart: More than expected?

    Article • Autoimmunity Reviews, September 2009, Elsevier

    Dr Maurizio Acampa, MD Pietro Enea Lazzerini

  137. Cannabinoids inhibit fibrogenesis in diffuse systemic sclerosis fibroblasts

    Article • Rheumatology, July 2009, Oxford University Press (OUP)

    MD Pietro Enea Lazzerini

  138. Human rheumatoid synoviocytes express functional P2X7 receptors

    Article • Journal of Molecular Medicine, June 2008, Springer Science + Business Media

    MD Pietro Enea Lazzerini

  139. Autoantibody-mediated cardiac arrhythmias: mechanisms and clinical implications

    Article • Basic Research in Cardiology, November 2007, Springer Science + Business Media

    Dr Maurizio Acampa, MD Pietro Enea Lazzerini

  140. Hyperhomocysteinemia: a cardiovascular risk factor in autoimmune diseases?

    Article • Lupus, November 2007, SAGE Publications

    MD Pietro Enea Lazzerini

  141. Comparison of Frequency of Complex Ventricular Arrhythmias in Patients With Positive Versus Negative Anti-Ro/SSA and Connective Tissue Disease

    Article • The American Journal of Cardiology, September 2007, Elsevier

    Dr Maurizio Acampa, MD Pietro Enea Lazzerini

  142. Hyperhomocysteinemia, inflammation and autoimmunity

    Article • Autoimmunity Reviews, August 2007, Elsevier

    MD Pietro Enea Lazzerini

  143. Psychosine‐induced apoptosis and cytokine activation in immune peripheral cells of Krabbe patients

    Article • Journal of Cellular Physiology, April 2007, Wiley

    MD Pietro Enea Lazzerini

  144. T Lymphocytes as Targets of Statins: Molecular Mechanisms and Therapeutic Perspectives

    Article • Inflammation & Allergy - Drug Targets, March 2007, Bentham Science Publishers

    MD Pietro Enea Lazzerini

  145. Correlation between cardiac oxidative stress and myocardial pathology due to acute and chronic norepinephrine administration in rats

    Article • Journal of Cellular and Molecular Medicine, January 2007, Wiley

    MD Pietro Enea Lazzerini

  146. Effects of acute administration of iloprost on the cardiac autonomic nervous system and ventricular repolarisation in patients with systemic sclerosis

    Article • Annals of the Rheumatic Diseases, June 2006, Elsevier

    MD Pietro Enea Lazzerini

  147. Connective tissue diseases and cardiac rhythm disorders: An overview

    Article • Autoimmunity Reviews, May 2006, Elsevier

    Dr Maurizio Acampa, MD Pietro Enea Lazzerini

  148. Cyclosporin and tacrolimus increase plasma levels of adenosine in kidney transplanted patients

    Article • Transplant International, March 2005, Frontiers

    MD Pietro Enea Lazzerini

  149. Corrected QT interval in anti‐SSA–positive adults with connective tissue disease: Comment on the article by Lazzerini et al

    Article • Arthritis & Rheumatism, February 2005, Wiley

    MD Pietro Enea Lazzerini

  150. Upregulation of A2A adenosine receptor expression by TNF-α in PBMC of patients with CHF: a regulatory mechanism of inflammation

    Article • Journal of Cardiac Failure, February 2005, Elsevier

    MD Pietro Enea Lazzerini

  151. Simvastatin inhibits T‐cell activation by selectively impairing the function of Ras superfamily GTPases

    Article • The FASEB Journal, January 2005, Wiley

    MD Pietro Enea Lazzerini

  152. The effects of age and hyperhomocysteinemia on the redox forms of plasma thiols

    Article • Journal of Laboratory and Clinical Medicine, November 2004, Elsevier

    Hieronim Jakubowski Jakubowski, MD Pietro Enea Lazzerini

  153. Simvastatin reduces MMP-3 level in interleukin 1β stimulated human chondrocyte culture

    Article • Annals of the Rheumatic Diseases, July 2004, Elsevier

    MD Pietro Enea Lazzerini

  154. Prolongation of the corrected QT interval in adult patients with anti-Ro/SSA-positive connective tissue diseases

    Article • Arthritis & Rheumatism, January 2004, Wiley

    Dr Maurizio Acampa, MD Pietro Enea Lazzerini

  155. Blunted increase in plasma adenosine levels following dipyridamole stress in dilated cardiomyopathy patients

    Article • Journal of Internal Medicine, November 2003, Wiley

    MD Pietro Enea Lazzerini

  156. Alteration in the redox state of plasma in heart-transplant patients with moderate hyperhomocysteinemia

    Article • Journal of Laboratory and Clinical Medicine, July 2003, Elsevier

    MD Pietro Enea Lazzerini

  157. Reduction in plasma homocysteine level in patients with rheumatoid arthritis given pulsed glucocorticoid treatment

    Article • Annals of the Rheumatic Diseases, July 2003, Elsevier

    MD Pietro Enea Lazzerini

  158. Changes of peripheral A 2A adenosine receptors in chronic heart failure and cardiac transplantation

    Article • The FASEB Journal, December 2002, Wiley

    MD Pietro Enea Lazzerini

  159. Oral low-dose dipyridamole protects from intravenous high-dose dipyridamole-induced ischemia. A stress echocardiographic study

    Article • International Journal of Cardiology, June 2002, Elsevier

    Dr Maurizio Acampa, MD Pietro Enea Lazzerini

  160. Early and delayed increase in plasma homocysteine levels in heart transplanted patients

    Article • Transplantation Proceedings, June 2002, Elsevier

    MD Pietro Enea Lazzerini

  161. Pravastatin treatment-associated reduction in plasma homocysteine in heart-transplanted patients

    Article • Transplantation Proceedings, June 2002, Elsevier

    MD Pietro Enea Lazzerini

  162. Cardiac dysautonomia in patients with superior vena cava syndrome due to compression by lung cancer

    Article • International Journal of Cardiology, February 2001, Elsevier

    Dr Maurizio Acampa, MD Pietro Enea Lazzerini

  163. Photopheresis immunomodulation after heart transplantation

    Article • Transplantation Proceedings, February 2001, Elsevier

    MD Pietro Enea Lazzerini

  164. Effects Of Dipyridamole And Adenosine On Vasoactive Peptides Calcitonin Gene‐Related Peptide And Atrial Natriuretic Peptide In Humans: Role Of Sympathetic Activation

    Article • Clinical and Experimental Pharmacology and Physiology, September 2000, Wiley

    MD Pietro Enea Lazzerini